Pure Global AI
NCT06420765Not yet recruiting

A Microneurography Study of NaV1.8 Inhibition in Healthy Adults

A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Effects of Single Doses of NaV1.8 Inhibitors on C-Nociceptor Action Potentials in Healthy Adults
Vertex Pharmaceuticals IncorporatedPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pain
Drug/Device/Intervention
VX-150
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Vertex Pharmaceuticals Incorporated
Timeline & enrollment
Phase
Phase 1
Start date
May 01, 2024
End date
Sep 01, 2025
Enrollment
40 participants
Primary outcome

Change From Baseline in Activity Dependent Slowing (ADS) Over Time

Summary

The purpose of this study is to determine the effects of Nav1.8 inhibition on
 activity-dependent slowing (ADS) of C-nociceptor nerve fibers, evoked action potential (AP)
 conduction velocity of C-nociceptor nerve fibers using VX-150 and VX-548.

ICD-10 classifications
Pain, unspecifiedPain, not elsewhere classifiedPain in limbAcute painOther chronic pain
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06420765
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06420765 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently Not yet recruiting. The study focuses on Pain. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.